“We are on the path to deliver a groundbreaking technology using novel cell-based platforms to deliver potent oncolytic viruses for the treatment of cancer.”

– Allan J. Camaisa, CEO and Chairman of Calidi Biotherapeutics.

JOURNAL ARTICLES

The Journal of Translational Medicine.
First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells
Journal Link: https://rdcu.be/bO8Ei

The Journal of Translational Medicine.
Rationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patients

Journal Link: https://rdcu.be/b4fPY 

Lancet Oncology
Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial

Publication Link: https://pubmed.ncbi.nlm.nih.gov/34214495/

 

CONFERENCES

ASCO-SITC Clinical Immuno-Oncology Symposium February 6-8, 2020 Orlando, Florida.
Abstract 21: A cell-based platform to potentiate oncolytic virus therapies.
AbstractPoster

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.
Abstract P609: First in man study of TK positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells
AbstractPoster

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.
Abstract P617: A cell-based platform to protect and enhance oncolytic virus therapies
AbstractPoster

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer | November 7-11, 2018 Washington, D.C.
Abstracts